Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 12.24%.

  • Tarsus Pharmaceuticals' EBIT Margin rose 400500.0% to 12.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.88%, marking a year-over-year increase of 845900.0%. This contributed to the annual value of 65.9% for FY2024, which is 7546300.0% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its EBIT Margin stood at 12.24% for Q3 2025, which was up 400500.0% from 21.61% recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' EBIT Margin ranged from a high of 33.07% in Q2 2021 and a low of 4274.56% during Q4 2021
  • Over the past 5 years, Tarsus Pharmaceuticals' median EBIT Margin value was 81.6% (recorded in 2024), while the average stood at 775.46%.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' EBIT Margin in the last 5 years was 41239500bps (2022), contrasted with its biggest fall of -36537500bps (2022).
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' EBIT Margin stood at 4274.56% in 2021, then soared by 96bps to 150.61% in 2022, then plummeted by -126bps to 339.94% in 2023, then surged by 89bps to 36.77% in 2024, then soared by 67bps to 12.24% in 2025.
  • Its last three reported values are 12.24% in Q3 2025, 21.61% for Q2 2025, and 33.55% during Q1 2025.